ATE447417T1 - Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie - Google Patents

Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Info

Publication number
ATE447417T1
ATE447417T1 AT05722089T AT05722089T ATE447417T1 AT E447417 T1 ATE447417 T1 AT E447417T1 AT 05722089 T AT05722089 T AT 05722089T AT 05722089 T AT05722089 T AT 05722089T AT E447417 T1 ATE447417 T1 AT E447417T1
Authority
AT
Austria
Prior art keywords
denotes
analogas
angiotensin
conjugates
peptide
Prior art date
Application number
AT05722089T
Other languages
German (de)
English (en)
Inventor
Dagfinn Lovhaug
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE447417T1 publication Critical patent/ATE447417T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05722089T 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie ATE447417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20040953 2004-03-04
PCT/NO2005/000078 WO2005084715A2 (en) 2004-03-04 2005-03-03 Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy

Publications (1)

Publication Number Publication Date
ATE447417T1 true ATE447417T1 (de) 2009-11-15

Family

ID=34918859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722089T ATE447417T1 (de) 2004-03-04 2005-03-03 Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie

Country Status (7)

Country Link
US (1) US7763234B2 (cg-RX-API-DMAC7.html)
EP (1) EP1729823B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007526300A (cg-RX-API-DMAC7.html)
CN (1) CN1925876A (cg-RX-API-DMAC7.html)
AT (1) ATE447417T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017475D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005084715A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
WO2006036071A2 (en) * 2004-09-29 2006-04-06 Ge Healthcare As Urokinase plasminogen activator receptor targeted contrast agent
AU2005307195A1 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
WO2010089757A2 (en) * 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
US9730916B2 (en) * 2014-02-27 2017-08-15 Chang Gung Memorial Hospital, Keelung Nutritional composition and method for improving heart failure
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966896A (en) 1974-09-06 1976-06-29 Mallinckrodt, Inc. Radioimmunoassay for plasma renin activity
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
WO1993012819A1 (en) 1992-01-03 1993-07-08 Rhomed Incorporated Protein- and peptide-metal ion pharmaceutical applications
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
CA2269985A1 (en) 1996-10-28 1998-05-07 Aslak Godal Improvements in or relating to diagnostic/therapeutic agents
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
JP5043271B2 (ja) 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
WO2002020610A2 (en) * 2000-09-07 2002-03-14 Biosynthema Inc. Conformationally constrained labeled peptides for imaging and therapy
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds

Also Published As

Publication number Publication date
CN1925876A (zh) 2007-03-07
DE602005017475D1 (de) 2009-12-17
JP2007526300A (ja) 2007-09-13
WO2005084715A2 (en) 2005-09-15
WO2005084715A3 (en) 2006-06-15
US20070297979A1 (en) 2007-12-27
EP1729823A2 (en) 2006-12-13
US7763234B2 (en) 2010-07-27
EP1729823B1 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
SG149895A1 (en) Contrast agents for myocardial perfusion imaging
IL180896A0 (en) Method of tumour imaging
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
ATE335515T1 (de) Morpholinobildgebung und therapie
GB0326546D0 (en) Inhibitor imaging agents
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
DK1272507T3 (da) Integrinbindende peptidderivater
BRPI0416628A (pt) uso de compostos orgánicos
EP2253333A3 (en) Contrast Agents for Myocardial Perfusion Imaging
EP1778351A4 (en) VERIFICATION OF LESIONAL FEATURES WITH BEAM SHAPES
TR199802139T2 (xx) Sisaprid'in an�nda tahliye sa�layan, PH'dan ba��ms�z kat� dozaj �ekli.
NO20072120L (no) Enzyme Inhibitor Imaging Agents
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
DE602005017475D1 (de) Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
ATE272074T1 (de) An neuropeptide gebundenes rgd (arg-gly-asp)
WO2005053752A3 (en) Novel imaging agents comprising caspase-3 inhibitors
EP2340845A3 (en) Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
ATE425770T1 (de) Kontrastmittel
ATE289612T1 (de) Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern
EA202192551A1 (ru) Способы диагностики рака легких
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
MA27772A1 (fr) Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons
BR0007702A (pt) Método e kit de diagnóstico para diagnose de endometriose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties